CVM Stock Forecast: CEL-SCI Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.20
−18.37% on the day

The median 12-month analyst price target for CEL-SCI Corp. is $13. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$25.9M
Ticker Nerd rank
38/ 100
Median analyst target
$13
Analysts covering
2
Revenue$0.0
Operating income−$5.6M
Net income−$5.7M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.3%
1M
−22.6%
YTD
−77.2%
1Y
−80.4%
From 52W high
−84.4%
From 52W low
+23.7%
$0.97
$7.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores CEL-SCI Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Growth
72
Issuance
51
Value
39
Quality
29
Volatility
22
Revisions
20
Momentum
18

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CVM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26CVMHigh $15Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$10
Low
$13
Median
$15
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 July 2023EF HuttonReiteratesBuy—
9 Mar 2023EF HuttonReiteratesBuy—
17 Feb 2023EF HuttonAssumesBuy$10
29 Dec 2022EF HuttonMaintainsBuy—
25 Aug 2022EF HuttonInitiatesBuy—
7 Apr 2022EF HuttonInitiatesBuy—
13 Jan 2020H.C. WainwrightInitiatesBuy—
13 Jan 2020HC Wainwright & Co.InitiatesBuy—
20 Feb 2013Taglich BrothersInitiatesSpeculative Buy—
13 Feb 2013Chardan CapitalInitiatesBuy—
14 Jan 2013Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CVM.

Market Radar

This page is one stock. Monday covers all of them.

CVM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CVM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, CEL-SCI Corp. returned −80.4% against +6.9% for the S&P 500, dividends included.

CVM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26CVMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−252.5%

Higher than 6% of US stocks

Return on assets
−66.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CEL-SCI Corp. has a market value of $25.9M and an enterprise value of $27.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$22.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.8M.

  • Shares outstanding: 17.6M.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CVM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CVMCEL-SCI Corp.$25.9M38
MGXMetagenomi Therapeutics, Inc.$21.2M33
ACETAdicet Bio, Inc.$20.5M30
CRVOCervoMed, Inc.$22.1M37
PLRZPolyrizon Ltd.$22.1M11
AARDAardvark Therapeutics, Inc.$20.1M15
RNAZTransCode Therapeutics, Inc.$19.6M12

Take a look at CVM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own CEL-SCI Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CVM

What is the CVM stock price forecast for 2026-2027?

The median 12-month analyst price target for CEL-SCI Corp. is $13, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVM stock a buy right now?

Of the 2 analysts covering CEL-SCI Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CEL-SCI Corp. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVM?

As at 21 Nov 2026, CEL-SCI Corp. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will CVM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $13, and Ticker Nerd's factor model ranks CEL-SCI Corp. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVM stock forecast for 2030?

No analyst covering CEL-SCI Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.

How has CVM stock performed over the past year?

CEL-SCI Corp. returned -80.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CEL-SCI Corp. do?

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and infectious diseases. Its principal investigational therapy, Multikine, is designed to activate and coordinate the immune system around the treatment of certain cancers, with research centered on improving outcomes through an integrated immune response.

Company

About CEL-SCI Corp.

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and infectious diseases. Its principal investigational therapy, Multikine, is designed to activate and coordinate the immune system around the treatment of certain cancers, with research centered on improving outcomes through an integrated immune response. The company also develops its Ligand Epitope Presentation System, or LEAPS, a platform intended to help direct immune responses toward disease-specific targets. CEL-SCI’s activities span biotechnology research, clinical development, pharmaceutical manufacturing, and regulatory preparation, positioning it within the specialized biopharmaceutical market. Its work addresses significant healthcare sectors, including oncology and infectious disease treatment, where immune-based approaches are an important area of medical research. Headquartered in Vienna, Virginia, CEL-SCI Corporation represents a development-focused biotechnology business whose market role is tied primarily to advancing investigational therapies and proprietary immune-modulation technologies rather than selling a broad portfolio of commercial medicines.

CEO Mr. Geert R. Kersten Esq. · United States · https://cel-sci.com